16.07.2012 - German pharmaceutical and chemical company Bayer sells the business with controversially debated drug Trasylol. The privately-held Dutch pharma The Nordic Group receives the worldwide marketing rights - except the US-territory.
The purchase price for Trasylol was not specified. In late 2008, health authorities in Germany and the United States told Bayer to stop distributing the aprotinin drug anywhere else. The trypsin inhibitor, which accounted for about EUR150m in annual sales, was used for complicated heart and liver surgery to reduce blood loss. In February this year, however, the EMA lifted the sales stop. The study results leading to the market ban had been incorrect said the Committee for Human Medicinal Products (CHMP). This positive opinion is expected to be ratified by the European Commission later in 2012. In Canada, the marketing stop had already been lifted in 2011. The Nordic Group is a European pharmaceutical company in private hands. Nordic claims to grow at an annual average rate of 20 percent. The company's focus is on niche products for hospitals and medicines for rare diseases.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.